Defining the clinical criteria for excellence in patient care
Pureprp® supraphysiologic - Nature’s regenerative powerhouse
PurePRP® SupraPhysiologic (PurePRP® SP) is a proprietary form of autologous platelet rich plasma developed by EmCyte Corporation. It contains a complex composition of cellular components derived from your blood biologic that can be used to treat and repair a host of injuries and conditions. It is the cornerstone of the consortium of regenerative therapies used in modern medicine and rapidly becoming a standard of care. It’s chosen over surgery for many conditions, ranging from degenerative joint disease, to tendon and ligament injuries because its regenerative power is shown to play an adjunctive role in clinical outcomes. It is unique in that it is the only point of care system that selectively removes wound inhibiting factors while concentrating regenerative cellular components. This powerful capability distinguishes the PURE SupraPhysiologic brand, making it the most dominant PRP in the overall market, according to Grand View Research project. Its wheelhouse is PURE POWER, PURE SIMPLICITY, and PURE HEALING.
The clear success of
PurePRP® supraphysiologic
There is a clear reason for the success of PurePRP® SP. It has the perfect cellular composition at ideal concentrations. It is a clinical marvel that’s not duplicated anywhere. PurePRP® SP provides the most powerful concentration of deliverable regenerative cells, without the deleterious contaminants found in most PRP products. The system exceeds the clinical requirement for effective PRP, providing between 7 and 21 billion platelets in a treatment sample. Unlike most PRP systems today, it DOES NOT create a diabetic condition at the injection site, of which is known to counter effective wound healing. The system removes red blood cell content, which is known to cause pain and inflammation at the injection site and it gives the practitioner control over its neutrophil content, allowing them to selectively treat wounds that require antimicrobial debridement or controlled inflammatory responses. The combined capability of PurePRP SP is unmatched at the point of care.
Deliverable platelets in PurePRP® supraphysiologic
Its All about the deliverables
Deliverable platelets are the actual volume of viable platelets contained in a platelet rich plasma (PRP) treatment sample. PurePRP® SupraPhysiologic provide between 7 and 21 billion platelets in a 7mL treatment sample, however the typical deliverables for patients with normal platelet counts are around 9 billion platelets. This is up to 2 billion higher than the minimum required treatment amount. High volumes of deliverable platelets enhances the volumetric activity of platelet growth factors and cytokines. Platelet alpha granules contain various platelet growth factors that can promote tissue repair along with platelet cytokines that can provide the chemical stimulus needed to attract and direct regenerative cells to injured tissue. Deliverable platelet count is the most important measure of the power of the PRP biologic.
Strength of neutrophil Granulocyte
Antimicrobial Inflammatory
Inflammatory Antimicrobial Power of neutrophils
Neutrophils are the most abundant of all leukocytes and first to migrate towards a site of injury or infection in a process is called chemotaxis. They are known to cause acute inflammation at the injury site as an aggressive response to chemical signals from cytokines. The primary antimicrobial function of the neutrophil is to engulf and destroy foreign material through phagocytosis. Under normal circumstances, neutrophils are short lived (1-2 days) and are cleared by tissue macrophages. In conditions where the neutrophils cannot be cleared, they undergo a process called necrosis resulting in the release of all of the intracellular contents. This causes the amplification and prolonging of the inflammatory response, which is of significant concern to practitioners.
Strength of classical Monocyte aGranulocyte
Antimicrobial non-inflammatory
Non Inflammatory Antimicrobial Power of Monocytes
Monocytes are the largest of all leukocytes and are abundantly non-inflammatory phagocytic cells better referred to as classical monocytes. They comprise about 80–95% of circulating monocytes and are known to be important scavenger cells. Monocytes migrate to sites of injury and infection and differentiate into macrophages and dendritic cells to elicit an immune response which last for longer periods of time when compared to neutrophils. Monocytes illicit the immune response through phagocytosis, antigen presentation, and cytokine production each of which has a specific and deliberate function in enhancing the immune response through both protective prophylaxis and active phagocytosis. Monocytes also participate in many other processes such as homeostasis, tissue repair, microbial resistance and maintenance of tissue integrity.
PurePRP® supraphysiologic
Antimicrobial versatility
Antimicrobial versatility of pureprp® supraphysiologic
PurePRP® SupraPhysiologic is unique in that it greatly enhances monocyte concentrations, while giving the end user control over the neutrophil content. Practitioners require this type of versatility in their PRP device because different wounds require different antimicrobial formulations. More specifically, infected wounds may benefit from the antimicrobial power of both high neutrophil and high monocyte biologic, but joint injections may benefit from the non-inflammatory antimicrobial response of monocytes without the acute inflammatory boost of neutrophils. Practitioners ultimately decide what is needed for their patients, but they appreciate the versatility offered by PurePRP SupraPhysiologic Concentrating System, another differentiating feature that help to explain its natural success.
A life changing application
The Treatment
PurePRP® SupraPhysiologic (SP) composition has been shown to improve the symptoms of or even cure many debilitating conditions involving the bone, joints or other tissue types. Patients have enjoyed great success when receiving this point of care therapy in place of surgery or other invasive intervention methods. The injection procedure is performed at the patient’s bedside. On the day of the procedure the patient is made comfortable while the treatment sample of PurePRP® SP is prepared by a qualified technician. The injection site is aseptically cleansed and then locally anesthetized. Using a small gauge needle, the physician will introduce the PurePRP® SP into the affected area using guided ultrasound or fluoroscopy. The injection procedure is usually completed in under 30 minutes. Afterwards the physician will provide careful instructions to follow during the outpatient recovery course. After application a set of bio-active processes take place leading to active tissue repair. This process goes on for weeks after just one application. Patients generally begin to see improvement in pain and mobility within weeks to months.
